Financhill
Back

Ultragenyx Pharmaceutical 10K Form

Sell
44

RARE
Ultragenyx Pharmaceutical

Last Price:
45.15
Seasonality Move:
-7.5%

7 Day Trial

ALL ACCESS PASS

$ 7

Receive RARE News And Ratings

See the #1 stock for the next 7 days that we like better than RARE

RARE Financial Statistics

Sales & Book Value

Annual Sales: $434.25M
Cash Flow: $-203.94M
Price / Cash Flow: 0
Annual Sales: $1.69
Price / Book: 29.15

Profitability

EPS (TTM): -8.03000
Net Income (TTM): $-613.35M
Gross Margin: $389.04M
Return on Equity: -384.83%
Return on Assets: -45.56%

Ultragenyx Pharmaceutical Earnings Forecast

Key Ultragenyx Pharmaceutical Financial Ratios

  • The Gross Profit Margin over the past 19 years for RARE is 89.59%.
  • The Selling, General & Administrative Expenses for RARE have been equal to 71.34% of Gross Profit Margin.
  • The Research & Development expenses have been 149.33% of Revenue.
  • The Interest Expense is -10.88% of Operating Income.
  • The Net Earning history of RARE is -139.70% of Total Revenues.
  • Per Share Earnings over the last 20 years have been positive in 8 years.

Ultragenyx Pharmaceutical Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: RARE
CUSIP: 90400D
Website: ultragenyx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 2.43
Quick Ratio: 2.09

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

RARE Technical Analysis vs Fundamental Analysis

Sell
44
Ultragenyx Pharmaceutical (RARE) is a Sell

Is Ultragenyx Pharmaceutical a Buy or a Sell?